Table 2.
Therapeutic efficacy of DTLL against human pancreatic carcinoma PDX models
| PDX models | Treatment groups | Number of mouse |
Tumor volume (mm3) Mean ± SD |
Inhibition rate Mean ± SD |
|---|---|---|---|---|
| PA1338 (High EGFR) | Vehicle | 5 | 1961.25 ± 202.51 | — |
| DTLL | 5 | 850.59 ± 95.25 | 56.63 ± 9.71a | |
| PA3029 (Low EGFR) | Vehicle | 5 | 857.24 ± 81.95 | — |
| DTLL | 5 | 604.87 ± 59.23 | 29.44 ± 13.82 |
PDX mice were administrated vehicle or DTLL at the LDM‐equivalent dose of 0.1 mg/kg once a week for 3 wk. Tumor volumes were measured after animals were sacrificed on Days 24 and 39, respectively. DTLL was administered via tail vein injection once a week for three weeks.
a
Compared with vehicle group, P < 0.001.